Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing
In patients on total parenteral nutrition, approximately 12 to 15 mM of phosphorus (equivalent to 372 to 465 mg elemental phosphorus) per liter bottle of TPN solution containing 250 g dextrose is usually adequate to maintain normal serum phosphorus, though larger amounts may be required in hypermetabolic states
In the TRIUMPH-1 trial, the 4 mg dose had a lower discontinuation rate due to adverse events than even placebo, suggesting that lower doses are well-tolerated
The study contributed to a developing preclinical literature suggesting AOD-9604 may have applications in joint and cartilage research distinct from its original metabolic indication
In laboratory settings, it is investigated for its role in actin dynamics and cell migration
